Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018 2019

Details for Mechanism ID: 16775
Country/Region: South Africa
Year: 2017
Main Partner: Aurum Institute
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $5,214,975 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,120,070
Care: TB/HIV (HVTB) $635,557
Laboratory Infrastructure (HLAB) $10,620
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $82,799
Testing: HIV Testing and Counseling (HVCT) $200,000
Sexual Prevention: Other Sexual Prevention (HVOP) $1,047,408
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: Adult Treatment (HTXS) $2,118,521
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST By Key Population: People in prisons and other enclosed settings, Negative 2018 26,144
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 29,453
HTS_TST Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Negative 2018 16
HTS_TST Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative 2018 707
HTS_TST Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative 2018 21,663
HTS_TST Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative 2018 11
HTS_TST Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative 2018 573
HTS_TST Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative 2018 105
HTS_TST Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative 2018 2,350
HTS_TST Service Delivery Point Agg Age (Facility) VMMC: 15+, Negative 2018 450
HTS_TST Sum of Test Result disaggregates 2018 3,504
HTS_TST_POS By Key Population: People in prisons and other enclosed settings, Positive 2018 3,488
HTS_TST_POS By Test Result: Positive 2018 3,504
HTS_TST_POS Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Positive 2018 6
HTS_TST_POS Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive 2018 231
HTS_TST_POS Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive 2018 2,912
HTS_TST_POS Service Delivery Point Agg Age (Facility) TB: 15+, Female, Positive 2018 3
HTS_TST_POS Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive 2018 76
HTS_TST_POS Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive 2018 16
HTS_TST_POS Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive 2018 376
HTS_TST_POS Service Delivery Point Agg Age (Facility) VMMC: 15+, Positive 2018 61
KP_PREV By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 71,122
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2018 71,122
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 47
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 1,298
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 1,346
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 1,345
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 47
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 1,293
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 14
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 459
TB_PREV By Therapy type (Numerator): Continuous IPT 2018 471
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 473
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 947
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 33
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 903
TB_PREV_den By Therapy type (Denominator):Continuous IPT 2018 932
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 31
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 2,691
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 2,722
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 2,838
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 31
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 2,807
TX_CURR Aggregated Age/Sex: 15+ Female 2018 641
TX_CURR Aggregated Age/Sex: 15+ Male 2018 25,025
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 25,666
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 25,666
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 25,666
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 157
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 4,601
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 4,754
TX_NEW People in prisons and other enclosed settings 2018 4,758
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 4,758
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 23,306
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 20,974
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 374
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 20,596
TX_PVLS Numerator: Indication: Routine 2018 20,974
TX_PVLS Unknown Age, Routine, Male 2018 4
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 42
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 663
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 22,588
TX_PVLS_den Denominator: Indication: Routine 2018 23,265
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 124
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 3,784
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 3,908
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 4,343
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 134
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 4,084
VMMC_CIRC By Age: 15-19 2018 107
VMMC_CIRC By Age: 20-24 2018 265
VMMC_CIRC By Age: 25-29 2018 198
VMMC_CIRC By Age: 30-49 2018 59
VMMC_CIRC By Age: 50+ 2018 21
VMMC_CIRC By circumcision technique: Device-based VMMC 2018 8
VMMC_CIRC By circumcision technique: Surgical VMMC 2018 642
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2018 650
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2018 650
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2018 393
Cross Cutting Budget Categories and Known Amounts Total: $1,400,000
Key Populations: MSM and TG $500,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Gender: Gender Based Violence (GBV) $100,000
GBV Prevention
Post GBV Care
Gender: Gender Equality $50,000
Equity in HIV prevention, care, treatment and support
Implementation
Capacity building
Human Resources for Health $700,000
Condoms: Policy, Tools, and Services $50,000